• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Fda warns against healthy life chemistry by purity
 

Fda warns against healthy life chemistry by purity

on

  • 1,322 views

FDA warns the consumers not to use Healthy life chemistry by purity first B-50 which contains hidden ingredients like Methasterone and Dimethazine.

FDA warns the consumers not to use Healthy life chemistry by purity first B-50 which contains hidden ingredients like Methasterone and Dimethazine.

Statistics

Views

Total Views
1,322
Views on SlideShare
1,322
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Fda warns against healthy life chemistry by purity Fda warns against healthy life chemistry by purity Presentation Transcript

    • FDA warns against Healthy Life Chemistry By Purity First B-50 P.Naina Mohamed Pharmacologist
    • Introduction  FDA is warning consumers that they should not use or purchase Healthy Life Chemistry By Purity First B-50, marketed as a vitamin B dietary supplement.  A preliminary FDA laboratory analysis indicated that the product contains two potentially harmful anabolic steroids—methasterone, a controlled substance, and dimethazine.  These ingredients are not listed in the label and should not be in a dietary supplement.
    • Methasterone  Methasterone is an anabolic steroid used as muscle-enhancing and body-building supplement and is a controlled substance. Mathasterone Analogue of Testosterone Slower metabolism Higher plasma level Mimic the anabolic action of Testosterone Increased muscle mass
    • Hepatotoxicity Methasterone Increase oxidative stress Impairment of canalicular bile salt export pump Irregulation of bile production Cholestasis, Jaundice
    • Cerebrovascular disease Methasterone May suppress prostacyclin production in arterial smooth muscle Increased risk of thrombin formation Cerebral infarction
    • Cardiovascular disease Chronic use of Methasterone Increased triglyceride lipase activity Reduction of HDL and elevation of LDL Increased risk of cardiovascular disease
    • Coronary Vasospasm Methasterone Inhibition of Guanylyl transferase enzyme Reduced synthesis of cGMP Inhibition of nitric oxide induced caronary vasodilation Coronary vasospasm
    • Gynecomastia Chronic use of Methasterone Induce Aromatase CYP19 enzyme Conversion of testosterone to estradiol Estradiol binds to estrogen receptor Gynecomastia
    • Dimethazine  Dimethazine contains two Methasterone molecules bound together by a nitrogen atom.  Dimethazine is less anabolic and more androgenic than Superdrol.  Dimethazine can not convert to estrogen and is free from estrogenic side effects.  It is fairly androgenic so androgenic side effects such as hair loss are a possibility with Dimethazine.  Dimethazine is dimethylated, so it does put significant stress on the liver.  A common side effect experienced with Dimethazine is painful muscle pumps/cramps, especially in the lower back and calves.
    • Conclusion  Health care professionals are advised to ask their patients about any dietary supplements they may be using, particularly in patients exhibiting warning signs that may be associated with the use of steroids or steroid-like substances.  These warning signs include liver injury, kidney failure and stroke. They also include hormone-associated adverse effects such as blood clots, including pulmonary embolism (a sudden blockage in a lung artery), and deep vein thrombosis (a blood clot that forms in a vein deep in the body, often in the lower leg or thigh).  Consumers using Healthy Life Chemistry By Purity First B-50 who experience symptoms should consult a health care professional and report their experience to the FDA.
    • References  http://www.fda.gov/Safety/MedWatch/SafetyInformat ion/SafetyAlertsforHumanMedicalProducts/ucm3628 00.htm?source=govdelivery  https://www.clinicalkey.com/#!/ContentPlayerCtrl/do PlayContent/1-s2.0-S1542356507011068  http://www.ncbi.nlm.nih.gov/pubmed/18563865.1  https://www.clinicalkey.com/#!/ContentPlayerCtrl/do PlayContent/1-s2.0-S1052305711002205  https://www.clinicalkey.com/#!/ContentPlayerCtrl/do PlayContent/1-s2.0-S0011502913000631